PuSH - Publikationsserver des Helmholtz Zentrums München

Grandl, G. ; Novikoff, A. ; Liu, X. ; Müller, T.D.

Recent achievements and future directions of anti-obesity medications.

Lancet Reg. Health-Eur. 47:101100 (2024)
Verlagsversion DOI PMC
Free journal
Creative Commons Lizenzvertrag
Pharmacological management of obesity long suffered from a reputation of a 'Mission Impossible,' with inefficient weight loss and/or unacceptable tolerability. However, the tide has turned with recent progress in biochemical engineering and the development of long-acting agonists at the receptor for glucagon-like peptide-1 (GLP-1), and with unimolecular peptides that simultaneously possess activity at the receptors for GLP-1, the glucose-dependent insulinotropic polypeptide (GIP) and glucagon. Some of these novel therapeutics not only improve body weight and glycemic control in individuals with obesity and type 2 diabetes with hitherto unmet efficacy and tolerable safety, but also exhibit potential therapeutic value in diverse areas such as neurodegenerative diseases, fatty liver disease, dyslipidemia, atherosclerosis, and cardiovascular diseases. In this review, we highlight recent advances in incretin-based therapies and discuss their pharmacological potential within and beyond the treatment of obesity and diabetes, as well as their limitations in use, side effects, and underlying molecular mechanisms.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Korrespondenzautor
Schlagwörter Anti-obesity Medication (aom) ; Diabetes ; Gip ; Glp-1 ; Obesity; Glucagon-like Peptide-1; Dependent Insulinotropic Polypeptide; Once-weekly Semaglutide; Glp-1 Receptor Agonist; Inhibits Bone-resorption; Double-blind; Cardiovascular Outcomes; Parallel-group; Body-weight; Open-label
ISSN (print) / ISBN 2666-7762
e-ISSN 2666-7762
Zeitschrift The Lancet Regional Health - Europe
Quellenangaben Band: 47, Heft: , Seiten: , Artikelnummer: 101100 Supplement: ,
Verlag Elsevier
Verlagsort Radarweg 29, 1043 Nx Amsterdam, Netherlands
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Obesity (IDO)
Förderungen German Center for Diabetes Research (DZD e.V.)
German Research Foundation
Neither the European Union
European Union